Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease
worldwide. One treatment is the use of metformin but its efficacy remains to be established …

The global prevalence of metabolic disorders, such as obesity, diabetes and fatty liver
disease, is dramatically increasing. Both genetic and environmental factors are well-known …

Summary Background The Practical guideline is based on the current scientific ESPEN
guideline on Clinical Nutrition in Liver Disease. Methods It has been shortened and …

Methods In total, 35 patients (14 lean and 21 obese) were included in the study. All patients
underwent transient elastography examinations, and controlled attenuation parameter …

Obesity is an escalating world problem that contributes to the complexity and cost of
treatment of metabolic disorders. Obesity is the result of increased storage of energy in the …

The aim of this study was to investigate the combined effect of n-3 fatty acids (EPA and DHA,
at an EPA: DHA ratio of 150: 500) and phytosterol esters (PS) on non-alcoholic fatty liver …

Athletes who retire from their sporting career face an increase in body weight, leading to
overweight or obesity. Simultaneously, a significant number of these athletes meet the …

Background Metastatic cancer is incurable and understanding the molecular underpinnings
is crucial to improving survival for our patients. The IGF-1/Akt signaling pathway is often …

Non-alcoholic fatty liver disease (NAFLD) is considered the major cause for the
development of chronic liver alterations. Hepatic steatosis is the most benign and common …

Scope Abdominal obesity is one of the main modifiable risk factors of age‐related
cardiometabolic disease. Cardiometabolic disease risk and its associated high abdominal …